en · de · es · pt
cardarine-notes.peptides6823.com › News › Cardarine As Investigational Pparδ Agonist — 2026 Update

Cardarine As Investigational Pparδ Agonist — 2026 Update

By Editorial Desk · published 2025-07-11 · last reviewed 2025-08-27 · News

fatty acid oxidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.

Cardarine as Investigational PPARδ Agonist

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Mechanism and Laboratory Detection

GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.

Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516, GW-501516, GW 501516, endurobolNames vary in research and anti-doping documents.
Chemical classSynthetic PPARδ agonistSmall-molecule nuclear receptor ligand.
CAS Registry Number317318-70-0Identifier commonly associated with GW501516.
AppearanceWhite to off-white powderTypical for purified research material.
SolubilityLow in water; soluble in DMSO and ethanolOrganic solvents are common for laboratory stock solutions.

Identity and Pharmacological Classification

Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Related pages on this site

Mechanism and Detection

Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

Background and Regulatory History

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Notes from published material

Silicon (Si) is the second most common element in the Earth's crust after oxygen. The compound silica, also known as silicon dioxide (SiO2), is formed from silicon and oxygen atoms. Since oxygen and silicon make up about 75% of the Earth's crust, the compound silica is quite common. It is found in many rocks, such as granite, sandstone, gneiss and slate, and in some metallic ores. Silica can be a main component of sand. It can also be in soil, mortar, plaster, and shingles. The cutting, breaking, crushing, drilling, grinding, or abrasive blasting of these materials may produce fine to ultra-fine airborne silica dust. Silica occurs in three forms: crystalline, microcrystalline (or cryptocrystalline) and amorphous (non-crystalline). "Free" silica is composed of pure silicon dioxide, not combined with other elements, whereas silicates (e.g., talc, asbestos, and mica) are SiO2 combined with an appreciable portion of cations.

== Biotechnology == The 7kDa proteins are valuable tools in biotechnology due to their ability to bind any dsDNA. When grafted onto a DNA polymerase, it greatly enhances the processivity of the enzyme by helping it stay bound to the DNA. Using such a modified enzyme allows a polymerase chain reaction to copy much longer pieces of DNA at a faster rate. Such fusion polymerases are sold under various tradenames under premium prices since 2014, but they can also be made and purified in a lab. (The commercial versions include additional mutations for performance.) The 7kDa protein scaffold is also a good starting point for artificial affinity proteins (affitins) that can be used to bind any molecule of interest. Techniques such as phage display are used to screen a wide variety of mutants and select for the good binders. Compared to antibodies, they are much smaller and much stabler.

== Early life == Dorothy Mary Crowfoot was born in Cairo, Egypt, the oldest of the four daughters whose parents worked in North Africa and the middle East in the colonial administration and later as archaeologists. Dorothy came from a distinguished family of archaeologists. Her parents were John Winter Crowfoot (1873–1959), working for the country's Ministry of Education, and his wife Grace Mary (née Hood) (1877–1957), known to friends and family as Molly. The family lived in Cairo during the winter months, returning to England each year to avoid the hotter part of the season in Egypt. In 1914, Hodgkin's mother left her (age 4) and her two younger sisters Joan (age 2) and Elisabeth (age 7 months) with their Crowfoot grandparents near Worthing, and returned to her husband in Egypt. They spent much of their childhood apart from their parents, yet they were supportive from afar. Her mother would encourage Dorothy to pursue the interest in crystals first displayed at the age of 10. In 1923, Dorothy and her sister would study pebbles that they had found in nearby streams using portable mineral analysis kit. Their parents then moved south to Sudan where, until 1926, her father was in charge of education and archaeology. Her mother's four brothers were killed in World War I and as a result she became an ardent supporter of the new League of Nations. In 1921 Hodgkin's father entered her in the Sir John Leman Grammar School in Beccles, England, where she was one of two girls allowed to study chemistry.

Sources: en.wikipedia.org

Background from the literature

== Morphology == These organisms specifically reside in the family Stichodactylidae or the “carpet anemones”. Defined by their distinct morphology, S. helianthus are large anemones that are sessile and range in diameter of 10–20 cm. Their color varies in shades of golden brown, yellow and green. They possess a multitude of nematocyst-coated tentacles that cover their flattened oral disc. The nematocysts play a large role in predation and defense by excreting toxins.

=== Citric acid cycle === α-Ketoglutarate is a component of the citric acid cycle, a cyclical metabolic pathway located in the mitochondria. This cycle supplies the energy that cells need by sequentially metabolizing (indicated by →) citrate through seven intermediate metabolites and then converting the eighth intermediate metabolite, oxaloacetate, back to citrate:

If a company transforms from a member state corporation to incorporate under the European Company Regulation 2001, employees are entitled to no less favourable representation than under the member state's existing board participation laws. This is practically important as a majority of EU member states require employee representation on company boards. Fourth, minimum job security rights are provided by three Directives. The Collective Redundancies Directive 1998 specifies that minimum periods of notice and consultation occur if more than a set number of jobs in a workplace are at risk. The Transfers of Undertakings Directive 2001 require that staff retain all contractual rights, unless there is an independent economic, technical or organisational reason, if their workplace is sold from one company to another. Last, the Insolvency Protection Directive 2008 requires that employees' wage claims are protected in case their employer falls insolvent. This last Directive gave rise to Francovich v Italy, where the Court of Justice affirmed that member states which fail to implement the minimum standards in EU Directives are liable to pay compensation to employees who should have rights under them.

Sources: en.wikipedia.org

Reference notes

Gordon Freeman is the silent protagonist of the Half-Life video game series, created by Gabe Newell and designed by Marc Laidlaw of Valve. His first appearance is in Half-Life (1998). Gordon is depicted as a bespectacled white man from Seattle, with brown hair and a signature circle beard, who graduated from MIT with a PhD in theoretical physics. He was an employee at the fictional Black Mesa Research Facility. Controlled by the player, Gordon is often tasked with using a wide range of weapons and tools to fight alien creatures such as headcrabs, as well as Combine machines and soldiers. Gordon's character has been well received by critics and gamers, and various gaming websites often consider him to be one of the greatest video game characters of all time, including UGO and GameSpot.

== Applications == Synthetic biology initiatives frequently aim to redesign organisms so that they can create a material, such as a drug or fuel, or acquire a new function, such as the ability to sense something in the environment. Examples of what researchers are creating using synthetic biology include:

T: + RC(O)CO2H → T=C(OH)R + CO2 T=C(OH)R + R'COOH → T! : + RC(O)CH(OH)R' Pyridoxal phosphate promotes decarboxylation of amino acids. Flavin-dependent decarboxylases are involved in transformations of cysteine. Iron-based hydroxylases operate by reductive activation of O2 using the decarboxylation of alpha-ketoglutarate as an electron donor. The decarboxylation can be depicted as such:

== Size exclusion chromatography == A study was done looking at the application of size exclusion chromatography in the purification of cross-link peptides within samples. When the eluted peptides were analyzed, cross-linked peptides could be detected at higher concentrations in the earlier fractions, eluting before modified or unmodified peptides.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Is cardarine a steroid?

No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.

Why was cardarine not developed further?

Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.

How is cardarine detected in samples?

Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.

Network